Cellumed, a company specializing in the manufacturing of bio-medical devices, announced on December 30 that it will strengthen its financial soundness through large-scale fundraising and accelerate the normalization of its management under a new major shareholder structure.
On the previous day, Cellumed disclosed that it has decided to conduct a third-party paid-in capital increase worth a total of 17 billion won, targeting TD Landmark Fund No. 1. Upon completion of this capital increase, the largest shareholder of the company is expected to change from InskoBi to TD Landmark Fund No. 1. The payment date for the paid-in capital increase is scheduled for January 22, 2026.
The company stated that it had been in discussions with multiple candidates who expressed investment interest in order to select the recipient of the paid-in capital increase. After comprehensively reviewing the business direction and conditions, Cellumed explained that it ultimately chose TD Landmark Fund No. 1 as its final partner, considering the shared vision and the ability to execute funding quickly.
Cellumed also noted that TD Landmark Fund No. 1 possesses an extensive network in the bio sector. A Cellumed representative said, "We expect our new partner's industry network to create synergies with our existing bio business," adding, "This will serve as an opportunity to expand our business scope beyond a simple capital inflow." The representative continued, "We have thoroughly verified the investor's financial status and funding capability, so we believe the investment will be completed according to the planned schedule."
The incoming 17 billion won will be used primarily to repay litigation-related debts. The company plans to resolve risks that have been a financial burden, thereby enhancing financial stability and corporate sustainability. At the same time, the funds will be used as operating capital to drive new business initiatives and improve the management environment.
Cellumed plans to reorganize its structure and establish a profit-oriented management system in light of the change in its largest shareholder. The company aims to make 2026 the first year of a performance turnaround, focusing its efforts on enhancing shareholder value and restoring market trust.
A Cellumed representative said, "We sincerely apologize to our shareholders who have trusted and waited for the company," adding, "Using the changes of a new major shareholder and an expanded network as a springboard, all executives and employees will work together to strengthen our fundamentals and prove our corporate value through improved performance."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
